Dutch startup goals to remotely monitor sufferers with its sensible stethoscope

Amsterdam-based Lapsi Health aims to firmly position itself in the rapidly evolving smart medical device market.

The startup announced yesterday the launch of its first clinical support tool, a digital stethoscope, in the US after receiving approval from the Food and Drug Administration (FDA) – the US medical device regulator.

The digital stethoscope, called Keikku, is a wearable wireless device that uses sensor technology and AI to listen to body sounds, such as breathing, and convert them into data-based insights.

Keikku also has features such as the ability to share and stream sound clips or trim and annotate them. These features are available in the stethoscope's app and web-based platform.

The Keikku stethoscope. Source: Lapsi HealthGig digital stethoscope

Lapsi Health says Keikku can improve patient screening and monitoring and is initially capable of improving diagnostics for a range of conditions such as respiratory, cardiac and gastrointestinal problems.

Back to business with the TNW conference

It's time to set your goals and budget for the coming year! Get 2 tickets now and save €€€ on this Super EarlyBird fare. Limited offer.

The startup is currently aimed at professionals in the general healthcare sector. However, the company's goal is to support individual use by patients in the future, which enables remote monitoring and treatment.

Screenshots from the Keikku digital stethoscope appThis is what Keikku's app looks like. Source: Lapsi HealthScreenshots from the Keikku digital stethoscope app

Plans for a wide range of medical devices

The launch of Keikku marks the first step in the company's commercialization journey.

Lapsi Health is also developing Ilo, a wearable fetal health monitoring device designed for pregnant women. Another upcoming product called Air is a wearable lung tracking device. The tools are currently in the validation or prototype stage.

The startup was founded in 2022 by Jhonatan Bringas Dimitriades (CEO), Diana van Stijn (Chief Medical Officer), Rodrigo Alvez (CTO) and Seamus Holohan (COO).

To date, the company has raised $5.8 million from pre-seed and seed rounds as well as scientific grants.

Comments are closed.